Inphact gains $15 million investment from MDS
Inphact gains $15 million investment from MDSMDS, a Canadian provider of laboratory and clinical services and products, has invested $15 million in Inphact, a Nashville, TN-based firm providing imaging and teleradiology services over the
Inphact gains $15 million investment from MDS
MDS, a Canadian provider of laboratory and clinical services and products, has invested $15 million in Inphact, a Nashville, TN-based firm providing imaging and teleradiology services over the Internet. The investment is intended to enable MDS to provide Inphact services on an exclusive basis in Canada and to MDS joint-venture facilities in the U.S. Inphact claims to be the first application service provider in the imaging market and is offering its PACS on a subscription basis over an ASP platform. The foundation of the firms platform is RadWeb, which provides browser-based access to radiology images and reports and the ability to manipulate and enhance digital images. Inphact plans to develop its ASP product for other imaging modalities, starting with cardiology.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
